Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876704 | 1.00 | S1PR1 (0.42) | S1PR1KCNA3TRPV1CCR2CTSK | |
| SCHEMBL1876702 | 1.00 | S1PR1 (0.42) | S1PR1KCNA3TRPV1CCR2CTSK | |
| SCHEMBL2195080 | 1.00 | S1PR1 (0.42) | S1PR1KCNA3TRPV1CCR2CTSK | |
| SCHEMBL30492178 | 1.00 | S1PR1 (0.42) | S1PR1KCNA3TRPV1CCR2CTSK | |
| SCHEMBL29730366 | 1.00 | S1PR1 (0.42) | S1PR1KCNA3TRPV1CCR2CTSK | |
| SCHEMBL12670597 | 0.93 | TAS1R3 (0.42) | KCNA3 | |
| SCHEMBL12434132 | 0.93 | TAS1R3 (0.42) | KCNA3 | |
| SCHEMBL4082429 | 0.87 | S1PR1 (0.40) | S1PR1KCNA3TRPV1CTSKGAA | |
| SCHEMBL5429659 | 0.87 | S1PR1 (0.40) | S1PR1KCNA3TRPV1CTSKGAA | |
| SCHEMBL24619628 | 0.85 | KDM4E (0.41) | S1PR1KCNA3TRPV1MAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3518922-B1 | COMPOUNDS AND METHODS FOR TREATING LUPUS | RECEPTOS LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-2498610-B2 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11278526-B2 | Compounds and methods for treating lupus | RECEPTOS LLC (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278526-B2 | Compounds and methods for treating lupus | S1PR1, S1PR2, SSB | S1PR1 1/4885KCNA3 2885/4885TRPV1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.